Morbidity and mortality of patients with invasive group A streptococcal infections admitted to the ICU

Chest

Volumn 130, Issue 6, 2006, Pages 1679-1686

  Mehta, Sangeeta ^a   McGeer, Allison ^b   Low, Donald E ^b   Hallett, David ^a   Bowman, Dennis J ^a   Grossman, Stacey L ^a   Stewart, Thomas E ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Group A streptococcus; ICU; ICU outcomes; Necrotizing fasciitis; Streptococcal toxic shock syndrome

Indexed keywords

BETA LACTAM ANTIBIOTIC; CLINDAMYCIN; HYPERTENSIVE FACTOR; IMMUNOGLOBULIN;

ADOLESCENT; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGE; AGED; APACHE; ARTERY CATHETERIZATION; ARTICLE; ARTIFICIAL VENTILATION; BLOOD CLOTTING DISORDER; CANADA; CLINICAL FEATURE; CORRELATION ANALYSIS; DEBRIDEMENT; DEMOGRAPHY; DISEASE SEVERITY; ENDOTRACHEAL INTUBATION; FEMALE; HISTOPATHOLOGY; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; KIDNEY DYSFUNCTION; LENGTH OF STAY; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORBIDITY; MORTALITY; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PULMONARY ARTERY CATHETER; RENAL REPLACEMENT THERAPY; SCORING SYSTEM; SHOCK; SINGLE DRUG DOSE; STREPTOCOCCUS GROUP A; STREPTOCOCCUS INFECTION; SURVIVAL RATE;

EID: 33845939764     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.130.6.1679     Document Type: Article

References (29)

1. Low DE, Schwartz B, McGeer A. The reemergence of severe group A streptococcal disease: an evolutionary perspective. In Scheld WM, Hughes JM, Murray BE, eds. Emerging pathogens 7. Washington, DC: American Society for Microbiology, 1998; 93-123
2. Baxter F, McChesney J. Severe group A streptococcal infection and streptococcal toxic shock syndrome. Can J Anesth 2000; 47:1129-1140
3. Davies HD, McGeer A, Schwartz B, et al. Invasive group A streptococcal infections in Ontario, Canada. N Eng J Med 1996; 335:547-554
4. Hoge CW, Schwartz B, Talkington DF, et al. The changing epidemiology of invasive group A streptococcal infections and the emergence of streptococcal toxic shock-like syndrome: a retrospective population based study. JAMA 1993; 269:384-389
5. Zurawski CA, Bardsley M, Beall B, et al. Invasive group A streptococcal disease in metropolitan Atlanta: a population-based assessment. Clin Infect Dis 1998; 27:150-157
6. Hollm-Delgado MG, Allard R, Pilon PA. Invasive group A streptococcal infections, clinical manifestations and their predictors, Montreal, 1995-2001. Emerg Infect Dis 2005; 11:77-82
7. Vlaminckx B, van Pelt W, Schouls L, et al. Epidemiological features of invasive and noninvasive group A streptococcal disease in the Netherlands, 1992-1996. Eur J Clin Microbiol Infect Dis 2004; 23:434-444
8. The Workshop Group on Severe Streptococcal Infections. Defining the group A streptococcal toxic syndrome: rational and consensus definition. JAMA 1993; 269:384-389
9. Kaul R, McGeer A, Low DE, et al. Population-based surveillance for group A streptococcal necrotizing fasciitis: clinical features, prognostic indicators, and microbiologic analysis of seventy-seven cases. Am J Med 1997; 103:18-24
10. Sharkawy A, Low DE, Saginur R, et al. Severe group A streptococcal soft-tissue infections in Ontario: 1992-1996. Clin Infect Dis 2002; 34:454-460
11. Knaus WA, Draper EA, Wagner DP, et al. APACHE II: A severity of disease classification system. Crit Care Med 1985; 13:818-829
12. Marshall JC, Cook DJ, Christou NV, et al. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med 1995; 23:1638-1651
13. Shtatland ES, Cain E, Barton MB. The perils of stepwise logistic regression and how to escape them using information criteria and the Output Delivery System. SUGI'26 Proceedings. Cary, NC: SAS Institute, 2001; paper 222-26
14. Working Group on Severe Streptococcal Infections. Defining the group A streptococcal toxic shock syndrome: rationale and consensus definition. The Working Group on Severe Streptococcal Infections. JAMA 1993; 269:390-391
15. Kotb M. Bacterial pyrogenic exotoxins as superantigens. Clin Microbiol Rev 1995; 8:411-426
16. Norrby-Teglund A, Kotb M. Host-microbe interactions in the pathogenesis of invasive group A streptococcal infections. J Med Microbiol 2000; 49:849-852
17. Holm SE, Norrby A, Bergholm A-M, et al. Aspects of the pathogenesis in serious group A streptococcal infections in Sweden 1988-1989. J Infect Dis 1992; 166:31-37
18. Eriksson B, Andersson J, Holm S, et al. Invasive group A streptococcal infections: T1M1 isolates expressing pyrogenic exotoxins A and B in combination with selective lack of toxin-neutralizing antibodies are associated with increased risk of streptococcal toxic shock syndrome. J Infect Dis 1999; 180:410-418
19. Norrby-Teglund A, Pauksens K, Holm SE, et al. Relation between low capacity of human sera to inhibit streptococcal mitogens and serious manifestation of disease. J Infect Dis 1994; 170:585-591
20. Basma H, Norrby-Teglund A, McGeer A, et al. Opsonic antibodies to the surface M protein of group A streptococci in pooled normal immunoglobulins (IVIG): potential impact on the clinical efficacy of IVIG therapy for severe invasive group A streptococcal infections. Infect Immun 1998; 66:2279-2283
21. Basma H, Norrby-Teglund A, Guedez Y, et al. Risk factors in the pathogenesis of invasive group A streptococcal infections: role of protective humoral immunity. Infect Immun 1999; 67:1871-1877
22. Norrby-Teglund A, Stevens DL. Novel therapies in streptococcal toxic shock syndrome: attenuation of virulence factor expression and modulation of the host response. Curr Dpin Infect Dis 1998; 11:285-291
23. Norrby-Teglund A, Muller MP, Mcgeer A. et al. Successful management of severe group A streptococcal soft tissue infections using an aggressive medical regimen including intravenous polyspecific immunoglobulin together with a conservative surgical approach. Scand J Infect Dis 2005; 37:166-172
24. Kaul R, McGeer A, Norrby-Teglund A, et al. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome: a comparative observational study. The Canadian Streptococcal Study Group. Clin Infect Dis 1999; 28:800-807
25. Darenberg J, Ihendyane N, Sjolin J, et al, and the StreptIg Study Group. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2003; 37:333-340
26. Demers B, Simor AE, Vellend H, et al. Severe invasive group A Streptococcal infections in Ontario, Canada: 1987-1991. Clin Infect Dis 1993; 16:792-800
27. Ben-Abraham R, Keller N, Vered R, et al. Invasive Group A streptococcal infections in a large tertiary center: epidemiology, characteristics and outcome. Infection 2002; 30:81-85
28. Mulla ZD. Invasive group A streptococcal disease and intensive care unit admissions. Intensive Care Med 2002; 28:1822-1824
29. Mulla ZD, Leaverton PE, Wiersma ST. Invasive group A streptococcal infections in Florida. South Med J 2003; 96:968-973